Chabner Colloquium


November 18, 2019
Boston, Massachusetts USA


Bruce Chabner

Founded by Dr. Bruce A. Chabner, this annual symposium, presented in joint partnership with the Massachusetts General Hospital Cancer Center, encourages dialogue among experts on topics that bring cancer biology to clinical application. The Chabner Colloquium is an intensive and thoughtful look at the potential for rational, collaborative drug development, tapping into the resources of government, pharmaceutical and biotech companies, and globally statured cancer centers of excellence.

Focusing on new targets and their interventions; strategies for profiling and selection of patients
for targeted drug trials; and biomarkers and animal models to guide clinical development, the entire drug development process is represented. The Chabner Colloquium provides a dialogue that influences trial design, hastens cancer drug development, and, long-term, will rationalize and lend efficiency to the practice of oncology.

2019 Chabner Colloquium

Session 1:
Promising New Targets for Drug Discovery and Development

(Overview) IDH Inhibition in Acute Myeloid Leukemia – Emergence of a New Therapeutic Era
Amir Fathi, MD
MGH/Harvard Medical School


Clonal Hematopoiesis
Benjamin Ebert, MD, PhD
Dana-Farber Cancer Institute


(Overview) Epigenetic Reversal of Chemotherapy Resistance in Cancers
Mo Motamedi, PhD
MGH Cancer Center

Session 2:
Junior Faculty Forum

(Overview) ctDNA, a Biomarker of Residual Disease and Tumor Response in Gastrointestinal Cancers
Aparna Raj Parikh, MD
Massachusetts General Hospital


(Overview) Cross-resistance in Small Cell Lung Cancer
Benjamin Drapkin, MD, PhD
MGH Cancer Center


(Overview) RET As a Target in Lung Cancer
Jessica J. Lin, MD
Massachusetts General Hospital


(Overview) Targeting SWI/SNF-Hippo Axis in Squamous Cancers
Srinivas Vinod Saladi, PhD
Massachusetts Eye and Ear Infirmary, MGH,
HMS, Broad Institute


Keynote Address

(Overview) Innovations in Cell Therapy
Marcela Maus, MD, PhD
MGH Cancer Center